Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Neuro Endocrine cells
  • Track 1-2Hypothalamus
  • Track 1-3Neurohypophysis
  • Track 1-4Adrenal glands
  • Track 1-5Pituitary glands
  • Track 2-1Brain Stroke
  • Track 2-2Autism and Schizophrenia
  • Track 2-3Neuropharmacology and Therapeutics
  • Track 2-4Therapies for genetic disorders
  • Track 3-1Cerebral aneurysms
  • Track 3-2Cerebral Arteriosclerosis
  • Track 3-3Cerebral atrophy
  • Track 3-4Cerebral Cavernous malformation
  • Track 3-5Cerebral hypoxia
  • Track 3-6Cerebral palsy
  • Track 3-7Cerebro Oculo Facio Skeletal syndrome
  • Track 3-8Accessory nerve disorder
  • Track 3-9CNS disorder and structural defects
  • Track 3-10Pseudotumor Cerebri
  • Track 3-11CSF Complications
  • Track 4-1Ataxia
  • Track 4-2Dystonia
  • Track 4-3Essential Tremors
  • Track 4-4Atypical Parkinsonisms
  • Track 5-1General Neurology
  • Track 5-2Child Neurology
  • Track 5-3Sports Neurology
  • Track 5-4Neuroethics
  • Track 5-5Vascular Neurology
  • Track 5-6Stem cells and regenerative Neurology
  • Track 5-7Functional Disorders and Behavioral Neurology
  • Track 5-8Neuropsychiatric disturbances
  • Track 5-9Investigating biomarkers
  • Track 5-10Developmental risk factors
  • Track 5-11Neurocognitive disorder
  • Track 5-12Childhood and adolescent psychiatry
  • Track 5-13Fundamentals of the clinical evaluation
  • Track 6-1Anterior,Central & Posterior Cord syndrome
  • Track 6-2Dementia
  • Track 6-3Alzheimers Disease Symptoms
  • Track 6-4Vasucular Dementia
  • Track 6-5Alzheimers Disease Pathophysiology
  • Track 6-6Hyper reflexia
  • Track 6-7Spasticy
  • Track 6-8Spine muscular atropies
  • Track 6-9Neuromuscular junction disorder
  • Track 6-10LambertEaton syndrome
  • Track 6-11Muscular dystrophy
  • Track 6-12Findings in the field of Neuromuscular medicine
  • Track 6-13Amyotrophic lateral sclerosis
  • Track 6-14Multiple sclerosis
  • Track 6-15Myasthenia gravis
  • Track 6-16Spinal muscular atrophy
  • Track 6-17Botulinum neurotoxin
  • Track 7-1Behavioural Neuroscience
  • Track 7-2Neuroglial Cells
  • Track 7-3Synaptic activities
  • Track 7-4Neurotransmitters
  • Track 7-5Synaptic Plasticity
  • Track 7-6Neuromyelitis Optica
  • Track 8-1Plastic Neurosurgery
  • Track 8-2Post-surgical neuralgias
  • Track 8-3Tumour and metastatis
  • Track 8-4Oncological neurosurgery
  • Track 8-5Spine neurosurgery
  • Track 8-6Current neurosurgery methods
  • Track 8-7Vascular Neurology
  • Track 8-8Neuroanaesthesia and surgery
  • Track 8-9Advancement in personalized medicine
  • Track 8-10Child Neurology
  • Track 8-11Cognitive Neurophysiology
  • Track 8-12Neurodegenrative disorders
  • Track 9-1Anti-anxiety Drugs
  • Track 9-2Recent Drug development
  • Track 9-3Neuroimmuno pharmacology
  • Track 9-4Latest advancement in Neuropharmacologcal therapy
  • Track 9-5Neuro chemical interaction
  • Track 10-1Electro physiologic techniques
  • Track 10-2Clinical neurophysiology
  • Track 10-3Advances in Electrodiagnostic Medicine
  • Track 10-4Application of Electrodiagnostic Medicine
  • Track 11-1Muscular Dystrophy
  • Track 11-2Spinal Muscular Atrophy (SMA)
  • Track 11-3Friedreichs Ataxia
  • Track 11-4Mitochondrial Myopathies
  • Track 11-5Metabolic Myopathies
  • Track 12-1Anxiety
  • Track 12-2Brain Machine Interface
  • Track 12-3Synaptic Pruning
  • Track 12-4Obsessive behavior
  • Track 12-5Attention deficit hyperactivity disorder (ADHD
  • Track 12-6 Brain-derived neurotrophic factor (BDNF)
  • Track 13-1Epidemiology of Brain stroke
  • Track 13-2Risk factors of Stroke
  • Track 13-3Haemorrage stroke and ischemic stroke
  • Track 13-4Amyotrophic lateral sclerosis (ALS)
  • Track 13-5Imaging, diagnosis and acute stroke management
  • Track 13-6Novel Insights for Parkinsons disease
  • Track 14-1Psycho Oncology
  • Track 14-2Radiation therapy
  • Track 14-3Neuropharmacology of cancer
  • Track 14-4Glioblastoma survival rate
  • Track 14-5Pediatric oncologist
  • Track 14-6Spine surgery
  • Track 14-7Inoperable brain tumor
  • Track 14-8Craniopharyngioma
  • Track 14-9Brain tumor
  • Track 14-10Butterfly glioma
  • Track 15-1Bipolar Disorder
  • Track 15-2Neuropathic pain syndromes
  • Track 15-3Accessory nerve disorder
  • Track 15-4CNS disorder and structural defects
  • Track 15-5Facial nerve paralysis
  • Track 15-6Meningitis
  • Track 15-7Therapies for genetic disorders
  • Track 16-1Catastrophic Injury
  • Track 16-2Stem cell Implantation
  • Track 16-3Paraplegia/Hemiplegia
  • Track 16-4Quadriplegia/Tetraplegia
  • Track 16-5Brown Sequard syndrome
  • Track 16-6Cauda equina syndrome
  • Track 17-1Neural tissue engineering
  • Track 17-2Biomarker in Neuroimaging
  • Track 17-3Advancement in brain computer interface
  • Track 17-4Current research in neural imaging
  • Track 17-5Biological neural networking
  • Track 17-6Neurobiotics
  • Track 17-7Biomolecular therapies in Neural regeneration
  • Track 18-1Huntington disease
  • Track 18-2Cancer genetics
  • Track 18-3Gene defect and diseases
  • Track 18-4Genome wide association studies
  • Track 18-5Biochemical genetics
  • Track 18-6Gene mutation and disease
  • Track 18-7Genetic engineering and Gene sequencing
  • Track 19-1Neuropsychiatric disturbances
  • Track 19-2Investigating biomarkers
  • Track 19-3Developmental risk factors
  • Track 19-4Neurocognitive disorder
  • Track 19-5Childhood and adolescent psychiatry
  • Track 19-6Fundamentals of the clinical evaluation
  • Track 19-7Advancement in personalized medicine